Meeting
2019 Genitourinary Cancers Symposium
Impact of new systemic therapies on outcomes of patients with non-metastatic castration resistant prostate cancer (nmCRPC).
Authors
Cecile Vicier
Institut Paoli Calmettes, Marseille, France
Cecile Vicier , Wanling Xie , Anis Hamid , Carolyn Evan , Christopher Sweeney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 244)
DOI
10.1200/JCO.2019.37.7_suppl.244
Abstract #
244
Poster Bd #
L1
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry.
First Author: Edoardo Francini
Poster
2016 Genitourinary Cancers Symposium
Sequencing of treatments in metastatic CRPC for patients who have completed all therapeutic interventions.
First Author: Allie E. Steinberger
Poster
2022 ASCO Quality Care Symposium
Real-world treatment patterns among men with metastatic castration-resistant prostate cancer (mCRPC) in the U.S. Medicare population.
First Author: Stephen J. Freedland
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the US.
First Author: Elisabetta Malangone-Monaco